1,109 reports of this reaction
1.9% of all BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, manufactured by INDIVIOR INC.. There are 1,109 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE to HEADACHE. This represents approximately 1.9% of all 59,605 adverse event reports for this drug.
Patients taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,109 FDA reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 1.9% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, making it a notable side effect.
If you experience headache while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.